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Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disorder with no effective treatment to 
date. Despite its multi-factorial aetiology, oxidative stress 
is hypothesized to be one of the key pathogenic mech-
anisms. It is thus proposed that manipulation of the 
expression of antioxidant genes that are downregulated 
in the presence of mutant SOD1 may serve as a thera-
peutic strategy for motor neuronal protection. Lentivi-
ral vectors expressing either PRDX3 or NRF2 genes were 
tested in the motor neuronal-like NSC34 cell line, and 
in the ALS tissue culture model, NSC34 cells expressing 
the human SOD1G93A mutation. The NSC34 SOD1G93A 
cells overexpressing either PRDX3 or NRF2 showed a sig-
nificant decrease in endogenous oxidation stress levels 
by 40 and 50% respectively compared with controls, 
whereas cell survival was increased by 30% in both 
cases. The neuroprotective potential of those two genes 
was further investigated in vivo in the SOD1G93A ALS 
mouse model, by administering intramuscular injections 
of adenoassociated virus serotype 6 (AAV6) expressing 
either of the target genes at a presymptomatic stage. 
Despite the absence of a significant effect in survival, dis-
ease onset or progression, which can be explained by 
the inefficient viral delivery, the promising in vitro data 
suggest that a more widespread CNS delivery is needed.
Received 11 February 2013; accepted 24 April 2013; advance online  
publication 4 June 2013. doi:10.1038/mt.2013.115
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) or motor neuron disease is 
a progressive neurodegenerative disorder that is characterized 
by the loss of upper and lower motor neurons of the spinal cord, 
brain stem and motor cortex. Approximately 5–10% of ALS cases 
are inherited in an autosomal dominant fashion, of which 15–20% 
of cases are caused by mutations in SOD1 (Cu/Zn superoxide dis-
mutase 1). Although ALS pathogenic mutations have been found 
in 19 genes and mutations in the newly identified C9ORF72 gene 
represent the most common cause of both familial and sporadic 
ALS,1,2 the SOD1 gene has been more widely studied and used to 
model ALS. In the presence of mutant SOD1, multiple interacting 
factors contribute to motor neuron injury including protein mis-
folding and aggregation, defective axonal transport, excitotoxicity, 
mitochondrial dysfunction, dysregulated transcription and RNA 
processing, endoplasmic reticulum stress, apoptosis, oxidative 
stress, and even toxicity caused by non-neuronal cells.3
Of these mechanisms, oxidative stress is considered to play a 
key role. Biochemical indices of free radical damage have been 
observed in cerebrospinal fluid and human post-mortem CNS tis-
sue of both familial and sporadic ALS cases.4,5 In addition, oxida-
tive damage has been observed in proteins,5 lipids,6 DNA,7 and 
also RNA species8 in post-mortem tissues from both familial and 
sporadic ALS cases. Furthermore, mutant SOD1 in microglia and 
astrocytes enhanced nitrogen oxides oxidation resulting in reac-
tive oxygen species production, and treatment with a nitrogen 
oxides inhibitor not only attenuated glial cell toxicity, but also 
increased significantly the life span of ALS mice.9 Thus, a thera-
peutic strategy delivering effective antioxidants could provide sig-
nificant protection of motor neurons in ALS.
Through both a genomic and a proteomic approach several 
genes have been identified, the expression of which is downregu-
lated in ALS models and the human disease. Two of them (NRF2 
and PRDX3) were chosen to be manipulated in their expression 
as a therapeutic strategy for the neuroprotection of motor neu-
rons and the two genes are antioxidant response element (ARE) 
genes.10–12 Peroxiredoxin 3 (PRDX3) is a mitochondrial thiore-
doxin–dependent hydroperoxidase, which catalyzes the reduction 
of peroxides in the presence of thioredoxin, and it is upregulated 
in response to oxidative stress.13 In particular, it directly interacts 
with the mitochondrial thioredoxin 2, and this system functions 
in parallel to the glutathione system to protect mitochondria from 
oxidative stress.14 Reduced PRDX3 expression may contribute to 
the mitochondrial morphological abnormalities seen in cellular 
and transgenic mouse models of ALS.15 Evidence of the neuropro-
tective ability of PRDX3 came from a study investigating Ebselen, 
a small molecule antioxidant drug that acts as a peroxiredoxin 
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mimic and offers neuroprotection by inducing transcription of 
ARE genes.12
Nuclear factor erythroid 2–related factor 2 (NRF2) is a basic 
leucine zipper transcription factor and is the principal component 
leading to ARE-mediated gene expression, a motif that is found 
in the promoter regions of detoxifying genes and antioxidant 
enzymes.16 NRF2 is sequestered in the cytoplasm by the actin-
bound protein KEAP1.17,18 NRF2 regulates many phase 2 detox-
ifying enzymes, and at least 14 genes controlled by NRF2 have 
been shown to be downregulated in the presence of mutant SOD1 
including antioxidant genes, and also genes involved in DNA 
repair, immune response and signaling.19,20 The mRNA and pro-
tein levels were decreased in the presence of mutant SOD1 trans-
fected cells, and similar findings were shown in primary motor 
cortex and spinal cord post-mortem tissue samples from patients 
with ALS with a reduction of NRF2 at both protein and mRNA 
levels, and a concomitant increase in KEAP1 mRNA levels.21 
Importantly, specific NRF2 overexpression in astrocytes of ALS 
mice resulted in decreased glial reactivity, delayed disease onset 
and increased mouse survival.22
Thus, these two antioxidant genes (PRDX3 and NRF2) were 
delivered through a lentiviral system in tissue culture models of 
ALS to assess their effect on cell survival and cellular oxidative 
stress levels. Both genes were then taken to the mouse model of 
the disease, as their viral delivery in cells showed decreased levels 
of oxidative stress by 50% and increased cell survival by 30%, with 
ultimate goal the development of an efficient therapeutic strategy.
RESULTS
LV-mediated neuroprotection in neuronal cells  
in vitro
LV-PRDX3–mediated significant protection against oxidative 
stress. After transduction of NSC34 cells with the lentiviral vec-
tor expressing PRDX3, quantification of transgene expression 
was assessed to determine optimal conditions defined as the 
maximum overexpression achieved at the lowest multiplicity of 
infection (MOI) without observing any cellular toxicity. NSC34 
cells transduced at an MOI of 20 exhibited a threefold PRDX3 
overexpression with this protein increase remaining stable for 
at least 2 weeks (Figure 1a–c). To explore the neuroprotective 
potential of PRDX3 overexpression, the transduced NSC34 cells 
were subjected to oxidative stress induction and the cell survival 
was determined by the MTT assay. After induction of oxida-
tive stress–mediated cell death through serum deprivation, the 
increase in survival of cells transduced with LV-PRDX3 was 
92% (N = 4, P < 0.001) compared with untransduced cells and 
61% (N = 4, P < 0.01) compared with LV-lacZ (β-galactosidase 
gene)–transduced cells (Figure 1d). The effect of higher levels of 
oxidative stress in the cells was evaluated by the administration of 
menadione for 6 hours, which acts by generating reactive oxygen 
species in multiple subcellular compartments through a redox 
cycling mechanism.23 NSC34 cells transduced with LV-PRDX3 
and treated with menadione exhibited increased cell survival, 
even though the difference compared with the untransduced cells 
did not reach statistical significance. This was probably due to the 
increased toxicity seen (76% cell death was seen in the untrans-
duced cells), which was beyond the compensatory upregulation of 
PRDX3 as the NSC34 cells are particularly vulnerable to oxidative 
stress. More importantly, virally delivered PRDX3 induced a 68% 
increase (N = 4, P < 0.001) in cell numbers under basal conditions 
compared with untransduced cells, and a 35% increase (N = 4, P < 
0.05) compared with NSC34 cells transduced with LV-lacZ, with 
the growth rate of the PRDX3-transduced cells being greater than 
controls.
Oxidative stress levels were also measured by the dichlorofluo-
rescein (DCF) assay to further investigate the effect of the virally 
delivered PRDX3 gene (Figure 1e). In particular, LV-PRDX3 
treatment led to a consistent and significant 30% decrease in oxi-
dative stress compared with the untransduced cells under basal 
conditions (N = 5, P < 0.01), and after serum deprivation (N = 5, 
P < 0.001) reaching a 40% reduction (N = 5, P < 0.01) when cells 
were treated with 10 µmol/l of menadione. The oxidative stress 
levels between untransduced cells and cells transduced with the 
viral control LV-lacZ were comparable throughout.
Having evidence of the protective ability of virally delivered 
PRDX3 in NSC34 cells, the vector was then tested in the exten-
sively characterized ALS tissue culture model, NSC34 cells stably 
expressing human SOD1G93A.24 In these cells, a threefold PRDX3 
protein overexpression was accomplished at 7 days after transduc-
tion with an MOI of 40 (MOI = 20 afforded only 1.5-fold protein 
increase; data not shown). As the oxidative stress response mecha-
nism of NSC34 SOD1G93A cells is already compromised leading to 
decreased viability, there was no need to induce additional stress 
and the cells were studied only under basal conditions (Figure 
1f–h). The cells overexpressing PRDX3 displayed a statistically 
significant 27% increase in cell survival compared with controls, 
and a significant 42% reduction in oxidative stress (N = 5, P < 
0.001). These results demonstrated that virally delivered PRDX3 
not only reduced the oxidative stress in non-transgenic cells upon 
stress and also cells carrying an ALS-causing SOD1 mutation, but 
furthermore, it protected cells from oxidative stress–mediated cell 
death. Thus, the PRDX3 gene was taken forward for additional 
studies in the in vivo model of ALS.
LV-NRF2–mediated significant protection against  oxidative 
stress. LV-NRF2 increases cell survival in both motor neuronal-like 
and astrocytic cell lines: The evaluation of NRF2 as a potential thera-
peutic target for ALS started with characterization of the viral vec-
tor construct and NRF2 protein expression. Despite a significant 
increase in mRNA levels after transduction with LV-NRF2, a con-
sistent increase in protein expression was not observed at the time 
points tested (Figure 2a–c). After further testing and optimization 
procedures (such as using various α-NRF2 antibodies with differ-
ent epitopes, changing western blot conditions, isolating nuclear 
fractions for NRF2 detection, using the HEK293 cells for transduc-
tion/transfection and protein detection), it was considered likely 
for an inherent issue with NRF2 overexpression to occur possibly 
due to a strict control by the cell of this transcriptional regulator.
Thus, a different approach was taken in respect to the LV-NRF2 
studies using reporter cell lines. After the dissociation of NRF2 from 
KEAP1 and its translocation to the nucleus, it binds to the ARE in 
the promoter region of detoxifying genes and antioxidant enzymes 
activating their expression.16,17 Induction of ARE-dependent tran-
scription would signify that NRF2 activation was accomplished. In 
2 www.moleculartherapy.org 
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Figure 1 LV-PRDX3–mediated protection in NSC34 and NSC34 SOD1G93A cells. (a) PRDX3 protein levels of NSC34 cells transduced with LV-PRDX3 
at 3 dpt relative to endogenous levels of untransduced cells (N = 3, mean ± SEM). (b) Representative western blot (25 μg of total protein per lane) of 
actin (47 kDa) and PRDX3 (27 kDa). (c) Time course of PRDX3 protein expression normalized to endogenous levels in NSC34 cells after transduction 
with LV-PRDX3 (MOI = 20). (d) NSC34 cell survival as determined by MTT assay at 5 dpt with LV-PRDX3 or LV-lacZ (MOI = 20) under basal conditions 
or after stress induction (two-way analysis of variance, Bonferroni’s post-hoc test, P < 0.05, N = 5, mean ± SEM). (e) NSC34 cellular oxidative stress 
levels determined for the same conditions as in d relative to the oxidative stress levels of the untransduced cells through the DCF assay (one-way 
analysis of variance, Tukey’s post-hoc test, P < 0.05, N = 5, mean ± SEM). (f) NSC34 SOD1G93A cell survival and (g) NSC34 SOD1G93A cellular oxidative 
stress levels, at 7 dpt with LV-PRDX3 or LV-lacZ (MOI = 40) under basal conditions (one-way analysis of variance, Tukey’s post-hoc test, P < 0.05, N = 5, 
mean ± SEM). (h) Each cell survival or oxidative stress assay was undertaken after verification of PRDX3 protein overexpression by western blot as 
shown in representative blots of NSC34 and NSC34 SOD1G93A cells. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. dpt, days post transduction; MOI, multiplicity 
of infection; PRDX3, peroxiredoxin 3.
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the absence of motor neuronal-like reporter cell lines, two astrocyte 
reporter cell lines were used; one stably expressing recombinant 
green fluorescent protein (GFP) under the control or the ARE pro-
moter, and one under the control of thymidine kinase promoter as an 
additional control. The GFP fluorescence was measured over time in 
untransduced cells representing the background fluorescence, and 
also in LV-lacZ– or LV-NRF2–transduced cells (Figure 2d). At the 
2nd day after transduction, a dramatic increase in fluorescence was 
seen in cells transduced with LV-NRF2 and expressing GFP under 
the ARE promoter, and this increase was seen for as long as the cells 
could be kept in culture (at least 5 days after transduction), with a 
positive correlation with the MOI used.
A possible way to limit the tight regulation of NRF2 might be 
the use of a cell line from a different species, as the small variations 
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in the sequence of human and mouse NRF2 might limit its sus-
ceptibility to regulation in a mouse or human cell line respectively. 
Thus, human and mouse astrocyte cells (astrocytes were used to 
the lack of a motor neuronal cell line of human origin) were trans-
duced with the LV-NRF2 vector that contains the mouse NRF2 
gene, and cell survival and oxidative stress levels were determined 
under basal and stress conditions (Figure 2e–h). As expected, 
human cells more easily overexpressed the mouse NRF2 offering 
a protection against oxidative stress, whereas the mouse cells regu-
lated NRF2 strictly and thus inhibited its overexpression. In human 
astrocytes, there was a small but significant increase of 10% under 
basal and serum deprivation conditions in LV-NRF2–transduced 
cells compared with controls with this increase reaching 30 and 
50% in the harsher stress condition of 10 and 30 µmol/l menadi-
one respectively, whereas no effect on the cell survival was seen on 
the mouse astrocytes (Figure 2e,f). Similarly, in human astrocytes 
transduced with LV-NRF2 a reduction (albeit not significant) in 
oxidative stress levels is seen under basal conditions, whereas after 
stress induction the oxidative stress levels are decreased by 40, 20, 
and 45% for conditions of serum withdrawal, 10 μmol/l and 30 μm 
menadione respectively (Figure 2g). In mouse astrocytes, despite 
the significant but small decrease in oxidative stress levels seen 
after serum withdrawal, no consistent reduction was seen between 
NRF2-transduced cells and controls (Figure 2h).
Despite the difficulties in detecting NRF2 protein overex-
pression, the effect of the LV-NRF2 in NSC34 SOD1G93A cells was 
investigated, as an effect might be seen due to the NRF2 down-
regulation11 and the impairment of proteasome10 in the presence 
of mutant SOD1. Interestingly, NSC34 SOD1G93A cells transduced 
with LV-NRF2 (MOI = 40) showed a significant 29% increase in 
cell survival and a corresponding 54% decrease in oxidative stress 
compared with LV-lacZ–transduced or –untransduced cells (N = 
5, P < 0.001) at 7 days after transduction (Figure 2i,j). In addition, 
it was considered whether LV-NRF2 could protect the already 
compromised NSC34 SOD1G93A cells from additional oxidative 
stress and thus, NSC34 SOD1G93A cells were further stressed by 
menadione and the relative survival rate was measured by MTT 
(Figure 2k). When the cells were stressed with 1 µmol/l menadi-
one, the cell survival of the LV-NRF2–transduced cells increased 
by 130%, whereas when stressed with 10 µmol/l menadione the 
cell survival reached a 373% increase compared with controls. The 
greatly increased cell survival in the cells expressing virally deliv-
ered NRF2 highlights the therapeutic potential of this gene.
Downstream gene expression changes after NRF2 modulation: 
To further elucidate the mechanism of action of NRF2, the pro-
tein and mRNA levels of several downstream genes of the NRF2 
pathway were studied in both transgenic and non-transgenic cell 
lines (Figure 3a–d). Two well-known antioxidants under the con-
trol of NRF2 were selected, HO1 and NQO1, and PRDX3 was also 
included as an added control of an antioxidant that does not act 
through the NRF2 pathway. It is particularly interesting to note 
that although in both NSC34 and NSC34 SOD1G93A cell lines there 
is an increase in NRF2 mRNA, in both cell lines there is no detect-
able protein overexpression, total or nuclear. Furthermore, the 
level of mRNA increase in NSC34 and NSC34 SOD1G93A is very 
different not only in NRF2 (10-fold and 20-fold respectively), but 
also in PRDX3 (2-fold and 10-fold respectively), HO1 (2-fold and 
6-fold respectively, and NQO1 (3-fold and 19-fold respectively) ( 
Figure 3a,b). These differences between the two cell lines might 
demonstrate a differential affinity for the viral transduction as all 
endogenous levels are comparable, leading to greater levels of the 
virally delivered target gene and subsequently greater activation of 
downstream genes.
It is noteworthy that this mRNA increase of the downstream 
genes corresponds to a protein overexpression in both cell lines. 
The protein levels in NSC34 and NSC34 SOD1G93A cells after 
LV-NRF2 transduction at 7 days after transduction were shown to 
be a fourfold and sevenfold increase respectively for HO1, a 5.5-
fold increase for NQO1 for both cell lines (Figure 3c,d). This acti-
vation of at least two downstream genes renders the viral delivery 
of NRF2 a very attractive strategy for treating ALS, as with the 
delivery of one gene, multiple other antioxidant and cytoprotec-
tive enzymes could be induced. Thus, evaluation of the effect of 
NRF2 overexpression in the in vivo model of ALS was considered 
worthwhile.
AAV6-mediated PRDX3 and NRF2 modulation in vivo
To evaluate the viral delivery of PRDX3 or NRF2 as a therapeutic 
strategy of ALS, an in vivo study was undertaken in the SOD1G93A 
mouse model. The two genes were transferred to an AAV6 viral 
construct to accomplish spinal cord motor neuronal delivery 
through intramuscular injections as previously undertaken,25,26 
and as a less invasive procedure than intraspinal, intrathecal, 
or intraventricular injections. Although the target tissue was 
the motor neuronal population, concomitant muscle transduc-
tion might confer some protective effects on the neuromuscular 
Figure 2 LV-NRF2–mediated protection in neuronal and astrocytic cells. (a) NRF2 protein levels of NSC34 cells transduced with LV-NRF2 at 3 dpt 
relative to endogenous levels of untransduced cells (N = 3, mean ± SEM). (b) Time course of NRF2 protein expression normalized to endogenous 
levels in NSC34 cells after transduction with LV-NRF2 (MOI = 40). (c) NRF2 mRNA levels in NSC34 cells normalized to endogenous actin levels after 
transduction with LV-lacZ or LV-NRF2 (5 dpt, MOI = 40; one-way analysis of variance, Tukey’s post-hoc test, P < 0.05, N = 3, mean ± SEM). (d) GFP 
fluorescence measured in human N1 astrocyte cell line carrying GFP under the TK promoter (solid bars) or under the ARE promoter (checkered bars) 
after transduction with LV-lacZ or LV-NRF2 at 1 and 2 dpt (two-way analysis of variance, Bonferroni’s post-hoc test, P < 0.05, N = 3, mean ± SEM). 
(e) Human N1 astrocyte survival or (f) mouse KT5 astrocyte survival, as determined by MTT assay and normalized to untreated untransduced cells, 
at 3 dpt with LV-NRF2 or LV-lacZ (MOI = 40) under basal conditions or after stress induction (two-way analysis of variance, Bonferroni’s post-hoc test, 
P < 0.05, N = 3, mean ± SEM). (g) Human N1 astrocyte or (h) mouse KT5 astrocyte, cellular oxidative stress levels determined for the same condi-
tions as in e,f relative to the oxidative stress levels of the untransduced cells through the DCF assay (one-way analysis of variance, Tukey’s post-hoc 
test, P < 0.05, N = 3, mean ± SEM). (i) Cell survival or (j) oxidative stress levels, of NSC34 SOD1G93A after transduction of LV-lacZ or LV-NRF2 (7 dpt, 
MOI = 40) normalized to values of untransduced cells (one-way analysis of variance, Tukey’s post-hoc test, P < 0.05, N = 5, mean ± SEM). (k) Cell 
survival of NSC34 SOD1G93A under basal and stress conditions after transduction of LV-lacZ or LV-NRF2 (7 dpt, MOI = 40) normalized to values of 
untreated untransduced cells (two-way analysis of variance, Bonferroni’s post-hoc test, P < 0.05, N = 3, mean ± SEM). *P ≤ 0.05, ***P ≤ 0.001. ARE, 
Antioxidant response element; dpt, days post transduction; GFP, green fluorescent protein; Men, menadione; MOI, multiplicity of infection; NRF2, 
nuclear factor erythroid 2–related factor 2; TK, thymidine kinase.
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junction. An AAV6-GFP vector was used as a viral control, and 
an untreated group was included to monitor the disease progres-
sion without any intervention. Unfortunately, no differences were 
found between the experimental groups and control groups for 
any outcome measurement including neurological score, age of 
onset, rotarod performance, survival or motor neuron cell sur-
vival27 (Figure 4a–g). Similarly, no differences were found for 
weight distribution, disease survival or various gait measurements 
as analyzed by the CatWalk system (data not shown). To elucidate 
whether this lack of effect was due to inefficient delivery or due to 
ineffectiveness of the therapeutic agents, a quantification of the 
transduction efficiency was necessary.
A previous pilot study undertaken by our lab had shown that, 
although western blot analysis verified very high protein over-
expression in muscle, the dynamic range of the technique did 
not allow the quantification of protein expression in spinal cord 
(Supplementary Figure S1). As such, a histological analysis was 
performed of the lumbar spinal cord. Lumbar spinal cord sections 
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Figure 3 Expression of downstream genes of the NRF2 pathway after transduction with LV-NRF2 vector. mRNA levels of PRDX3, NRF2, HO1 
and NQO1 normalized to endogenous actin levels as assessed by quantitative PCR in (a) NSC34 and (b) NSC34 SOD1G93A cells transduced with 
LV-lacZ, LV-PRDX3 or LV-NRF2 (7 dpt, MOI = 40; one-way analysis of variance, Tukey’s post-hoc test, P < 0.05, N = 3, mean ± SEM). (c) Representative 
western blots of NRF2 (68 kDa), NQO1 (31 kDa) and HO1 (35 kDa) protein expression levels in NSC34 and NSC34 SOD1G93A cells after transduc-
tion with LV-lacZ, LV-PRDX3 or LV-NRF2 (3 and 7 dpt, MOI = 40, N = 3). (d) Quantification through densitometric analysis of protein expression of 
NRF2, NQO1 and HO1 expressed to the endogenous levels of untransduced cells and normalized to actin levels after LV-lacZ, LV-PRDX3 or LV-NRF2 
transduction (7 dpt, MOI = 40; two-way analysis of variance, Bonferroni’s post-hoc test, P < 0.05, N = 3, mean ± SEM). ***P ≤ 0.001. dpt, days post 
transduction; HO1, hemeoxygenase 1; MOI, multiplicity of infection; NQO1, NAD(P)H quinine oxidoreductase 1; NRF2, nuclear factor erythroid 
2–related factor 2; PRDX3, peroxiredoxin 3.
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from three mice, which were sacrificed after reaching the animal 
study endpoint, were stained with fluorescent antibodies against 
GFP (green) and choline acetyltransferase (red) as a neuronal 
marker, and analyzed by fluorescence microscopy to detect the 
AAV6-GFP–transduced motor neurons (Figure 5). The transduc-
tion efficiency was calculated as the ratio of transduced motor 
neurons to total motor neurons, and as seen in Table 1, <5% of 
the surviving lumbar motor neurons were transduced. This low 
level of gene transfer could adequately explain the absence of any 
therapeutic effect in the in vivo model.
DISCUSSION
The therapeutic potential of PRDX3 and NRF2 genes was demon-
strated in a tissue culture model of SOD1-related ALS suggesting 
that they could be used as therapeutic interventions. In agree-
ment with other reports, we found that viral delivery of PRDX3 
protected the cells against oxidative stress insults supporting its 
application to in vivo systems.28 To further support the therapeu-
tic potential of virally delivered PRDX3 to motor neurons, the 
distribution of PRDX3 in neural cell types should be taken into 
account. A study investigating the differential expression patterns 
of all the members of the peroxiredoxin family reported histo-
logical evidence that no PRDX3 immunoreactivity was seen in 
astrocytes or glial cells in the brain.29 This supports our hypothesis 
that direct delivery to the motor neurons might offer protection 
against oxidative stress. Furthermore, decreased PRDX3 levels 
have been observed in brain regions from patients suffering from 
Down syndrome, Parkinson’s and Alzheimer’s disease, suggesting 
Figure 4 Efficacy study of AAV6-PRDX3 and AAV6-NRF2 in SOD1G93A mice. (a) Changes in neurological score (average score per group) over time 
in experimental mice (N = 15 mice per group, two-way analysis of variance, Bonferroni’s post-hoc test, P < 0.05, mean ± SEM). (b) Comparison of 
the average age of onset between experimental groups as calculated by neurological scoring (N = 15 mice per group, two-way analysis of variance, 
Bonferroni’s post-hoc test, P < 0.05, mean ± SEM). (c) Rotarod performance (i.e., ability of mice to run in seconds) over time between experimental 
groups with the dashed line depicting a 20% reduction in rotarod performance (N = 15 mice per group; two-way analysis of variance, Bonferroni’s 
post-hoc test, P < 0.05, mean ± SEM). (d) Kaplan–Meier plot to compare lifespan between all experimental groups (N = 15 per group; P < 0.05). 
(e,f) Representative lumbar spinal cord sections from untreated control SOD1G93A mice, fixed and stained with Nissl substance. Scale bars are shown 
at the bottom right corner (e, 200 μm; f, 100 μm). (g) Quantification of motor neurons (average number per section per group) by counting across 
all groups (N = 5; one-way analysis of variance, Bonferroni’s post-hoc test, P < 0.05, mean ± SEM). AAV6, adenoassociated virus serotype 6; GFP, green 
fluorescent protein; NRF2, nuclear factor erythroid 2–related factor 2; PRDX3, peroxiredoxin 3.
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both a common role for oxidative stress in different neurological 
disorders and a potential common approach to treatment.30,31
The importance of NRF2 as a therapeutic strategy is high-
lighted by the fact that in primary motor cortex and spinal cord 
post-mortem tissue samples from patients with ALS a reduction 
of NRF2 at both protein and mRNA levels, and a concomitant 
increase in KEAP1 mRNA levels was shown.21 Importantly, spe-
cific NRF2 overexpression in astrocytes of ALS mice resulted in 
decreased glial reactivity, delayed disease onset and increased 
mouse survival.22 Furthermore, a neuronal cell line expressing 
mutant TDP-43 exhibited increased neurite outgrowth when 
treated with MG132 by inducing an upregulation in HO1.32 
Although the increased expression of HO1 was independent of 
the NRF2 pathway, HO1 is regulated by NRF2 and an induction of 
NRF2 could in turn lead to HO1 overexpression. As in this project 
the viral delivery of NRF2 lead to overexpression of downstream 
genes of the NRF2 pathway, neuroprotection could potentially be 
induced independently by other antioxidant genes of the pathway.
Nonetheless, it has proven very difficult to consistently 
overexpress the NRF2 protein, and the results presented in this 
paper suggest that mutant SOD1-induced alteration of the gene 
expression profile of neuronal cells allows sufficient upregulation 
of NRF2 to confer neuronal protection. Nonetheless, without a 
clear understanding of the mechanism of NRF2 regulation, it is 
difficult to evaluate the clinical application of such an approach. 
Although the mechanism of NRF2 regulation is not clear yet 
despite the extensive research, it has been suggested that a very 
rapid response to stress changes the balance of the nuclear import 
and export of the protein promoting nuclear accumulation and 
thus subsequent transcriptional activation.33 In particular, upon 
cellular treatment with an NRF2 inducer, NRF2 accumulated in 
the nucleus within 15 minutes, and between 1 and 4 hours after 
treatment NRF2 started exiting the nucleus reaching normal cyto-
solic localization in a total of 8 hours.33 Such a dynamic regulation 
of NRF2 could impose difficulties in detecting it when consider-
ing its rapid turnover.
Thus, in the case of the non-transgenic NSC34 cells, it is possi-
ble that after transduction with LV-NRF2, an autoregulatory loop 
was initiated shortly after the expression of the viral NRF2, and it 
has been observed that transgene expression can be detected as 
early as 2 days after transduction. Protein levels were not evalu-
ated after the oxidative stress insult, and the stress induction might 
have been too long for quantification of overexpression (at least 1 
hour). On the other hand, the inconsistent NRF2 protein levels in 
NSC34 SOD1G93A cells might be explained by a continuous cycle of 
NRF2 induction and inhibition. In this case, the increased oxida-
tive stress caused by mutant SOD1 could upregulate NRF2, and 
its upregulation in combination with the virally delivered NRF2 
could induce its inhibition. This phenomenon could provide short 
“bursts” of NRF2 activity, and induction of ARE transcription. As 
the downstream genes activated by NRF2 do not have such a read-
ily activated degradation pathway, the cytoprotection seen could 
be due to their transcription, but further investigation is needed 
to substantiate this.
Although the work presented here cannot describe conclu-
sively a mechanism of action for NRF2, it provides pointers for 
further investigation. A tight time course experiment, in which 
protein lysates are extracted from cells transduced with LV-NRF2 
every few hours, will provide a clear picture of the protein expres-
sion over time, and also how quickly it is suppressed by the cell. 
Furthermore, concomitant inhibition of genes negatively regu-
lating NRF2 (such as KEAP1) will give evidence for the design 
of strategies for inducing a stable protein overexpression. This 
could be accomplished either by the co-transduction of cells using 
two viral vectors (for example, one expressing NRF2 and one 
expressing siRNA against KEAP1), or by a bidirectional vector. 
Table 1 Transduction efficiency of lumbar motor neurons of SOD1G93A 
mice
Mouse
Total motor 
neurons
Transduced  
motor neurons
Transduction 
efficiency
1 495 29 5.9%
2 398 17 4.3%
3 492 18 3.7%
Average 4.6%
Figure 5 Transduction efficiency of spinal motor neurons in 
SOD1G93A mice. Lumbar spinal cord sections from SOD1G93A mice treated 
with AAV6-GFP were fixed and labeled with (a,e) ChAT antibody as a 
neuronal marker, (b,f) GFP antibody as an indicator of transduction, and 
(c,g) DAPI for nuclear visualization. Pictures on the left (a–d) were taken 
using ×20 magnification (50 μm scale bar), and on the right (e–h) using 
×63 magnification (20 μm scale bar). AAV6, adenoassociated virus sero-
type 6; ChAT, choline acetyltransferase; GFP, green fluorescent protein.
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Alternatively, known inducers of NRF2 could be used in combi-
nation with the viral vectors to examine their effect on protein 
regulation
When the PRDX3 and NRF2 genes were taken forward to the 
animal model, no beneficial effect was seen compared with con-
trols (untreated or AAV6-GFP–treated mice). However, <5% of 
the spinal motor neurons were transduced and such a low trans-
duction efficiency would be unlikely to be sufficient to induce a 
therapeutic effect. Moreover, it is likely that the actual percent-
age of transduced neurons is even lower assuming the transduced 
neurons survive longer, as by the end-stage of the disease there is 
a substantial motor neuron loss.34 When assessing the transduc-
tion efficiency in the muscle, it was seen that all muscle groups 
injected expressed the transgene very strongly (Supplementary 
Figure S1). Although the transgene expression was not wide-
spread within the whole muscle and it persisted in an area sur-
rounding the injection site, the expression was so strong that the 
muscle injected with AAV6-GFP could be recognized by naked 
eye. This observation indicated that overexpression of NRF2 and 
PRDX3 in the muscle is not likely to affect the disease course in 
SOD1G93A transgenic mice.
Recombinant AAV are capable of neuronal retrograde trans-
port when delivered to skeletal muscle,35 and AAV6 has been 
shown to induce a widespread skeletal muscle transduction.36 
Thus, the motor neuronal population could be targeted by admin-
istering the viral vector directly into muscle. However, there is 
increasing evidence that the toxicity caused by mutant SOD1 is 
not cell-autonomous, and a therapeutic strategy targeting motor 
neurons might not be sufficient to influence the disease course.37–41 
When intramuscular injections of AAV6 expressing shRNA for 
silencing mutant SOD1 in the hind limbs were performed, 3.2% 
transduction efficiency was accomplished in the motor neurons 
of the lumbar spinal cord.42 As expected, the disease progression 
was not altered, even though the protein levels in the muscle were 
reduced by >50%. The authors then tried to administer body-wide 
intramuscular injections in neonatal SOD1G93A mice in an attempt 
to increase the transduction efficiency.26 Although this approach 
resulted in enhanced delivery, motor neuronal protection, and 
also muscle atrophy attenuation, it did not confer a therapeutic 
impact on disease progression.
Hence, it is likely that a motor neuronal delivery might not 
be sufficient to modify the disease, and a more widespread CNS 
administration may be needed. With the development of the 
AAV9 serotype that appears to cross the blood–brain barrier, a 
new delivery option has been presented with unique advantages. 
It would be also of great interest to identify whether a systemic 
or CNS-targeted delivery could reach therapeutic levels. Parallel 
experiments in mice comparing a CNS delivery by administering 
the viral vector through intraspinal or intrathecal injection, and 
systemic delivery by administration though intravenous injec-
tions, will elucidate the most appropriate protocol, and the impor-
tance of a widespread therapeutic strategy.
MATERIALS AND METHODS
Viral vector production. The cDNAs encoding for the reporter gene lacZ, 
the GFP gene and the mouse genes of interest (PRDX3 and NRF2) contain-
ing a Kozak consensus sequence (GCCACC) were subcloned either into the 
pIRES or TOPO pCRII vectors. They were then subcloned using appropri-
ate sites in the destination expression viral vectors (SIN-PGK-cPPT-WHV 
vector for the LV viral vectors or ScAAV2-CMV-GFP for the AAV6 viral 
vectors). All constructs were confirmed by restriction enzyme digestions 
and sequencing. LV pseudotyped with the vesicular stomatitis virus-G 
envelope protein were generated by calcium phosphate 4-plasmid (SIN-W-
PGK, pCMVΔR8.92, pMD.G, and pRSV-Rev) cotransfection of HEK293T 
cells as previously described.43 The titers of the viral stocks were obtained 
by p24 (capsid antigen) ELISA assay (ZeptoMetrix, Buffalo, NY) following 
manufacturer’s recommendations with serial dilutions of LV vectors. The 
AAV6 expressing PRDX3 was generated in house by calcium phosphate 
2-plasmid (AAV6-PRDX3 and pDGM6) cotransfection of HEK293T cells 
as previously described.36 Vector purification was accomplished by affin-
ity chromatography (AKTAprime plus purification system; GE Healthcare, 
Amersham, UK) using a heparin column (HiTrap heparin HP Column; 
GE Healthcare) and the crude viral vector solution was collected after elu-
tion in HBSS containing 400 mmol/l NaCl.44 After filtering through 0.2 µm 
filter and concentrating the viral solution by ultra-centrifugation through a 
sucrose cushion (Sigma, Dorset, UK), the pellets were resuspended in 230 
µl HBSS. An aliquot of 30 µl was kept for Coomassie staining and analysis 
of titre through quantitative PCR. All preparations with a titre <1 × 1012 
viral particles per ml were discarded, whereas the rest were diluted and 
aliquoted to 120 μl with a titre of 1 × 1012 viral particles per ml. AAV6-
NRF2 and AAV6-GFP viral vectors were prepared by Virapur (Virapur, 
San Diego, CA) and by the Gene Therapy Centre (University of North 
Carolina, Chapel Hill, NC), and the titres of both viral vectors were veri-
fied by quantitative PCR, diluted if needed and aliquoted to 120 μl (1 × 1012 
viral particles per ml titre).
Cell lines and lentiviral transduction. NSC34 cells, a hybrid mouse motor 
neuron-neuroblastoma cell line45 were used for the cell assays and western 
blots. NSC34 cells stably transfected with the G93A mutant human SOD1 
cDNA were also used and cultured under the selection pressure of G418 
antibiotic.24 HEK293T cells were used for LV production, and HEK293D 
cells (kindly provided by Jeffrey Chamberlain, University of Washington 
School of Medicine, Seattle, WA) were used for the AAV production. 
Human N1 astrocytes (1321N1 cell line; ECACC, Salisbury, UK) and 
mouse KT5 astrocytes (JCRB Cell Bank, Ibaraki City, Osaka, Japan) were 
also used for the oxidative stress levels measurement assay. Furthermore, 
human N1 astrocyte reporter cell lines were used, which were stably trans-
fected with the GFP either under the thymidine kinase promoter or under 
the ARE promoter. Lentiviral transduction efficiency of all cell lines was 
assessed by immunofluorescence and cell counting, and standardized per 
cell line. Appropriate viral vector concentrations were used to achieve the 
maximum non-toxic transduction ratio of 85–90% for NSC34 and NSC34 
SOD1G93A cells, and 95–100% for N1 and KT5 astrocytes.
Oxidative stress levels measurement and cell viability assays. Cellular 
oxidative stress was induced by serum withdrawal or menadione for 6 
hours. Reduction of 0.1 volumes of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrasodium bromide (MTT; Sigma) by cellular dehydroge-
nases was used to quantify the number of living cells in 96-well plates. 
After 1 hour incubation at 37°C, 1 volume of DMF/SDS (20% SDS in 50% 
DMF, pH 4.7) was added to each well at room temperature on a shaking 
platform for 1 hour and the absorbance was determined at 595 nm. For 
measurement of the oxidative stress levels, the DCF (10 mmol/l 6-carboxy-
2′,7′-dichloro-dihydrofluorescein diacetate di (acetoxymethyl) ester, 
Invitrogen, Paisley, UK) dye was added to cells at a final concentration of 
5 µmol/l. Oxidative stress levels were measured by the increase in fluo-
rescence of the DCF dye (excitation at 485 nm and emission at 530 nm), 
and a read was taken before the addition of the dye to account for back-
ground fluorescence. The toxicity of the assay was monitored by adding 
ethidium homodimer-1 dye (Invitrogen). It was added concurrently with 
the addition of the DCF dye at a final concentration of 0.33 µmol/l, and 
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the fluorescence was measured at excitation wavelength of 530 nm and 
emission wavelength of 645 nm. To account for the experimental varia-
tion in plating or differential growth rate of cells, the data were normalized 
according to the cell number obtained by the MTT assay performed on the 
same plates after the completion of the DCF assay.
Quantitative PCR. Total RNA was extracted with the SV total RNA iso-
lation system (Promega, Southampton, UK), and cDNA was synthesized 
using SuperScript III First-Strand Synthesis System (Invitrogen) according 
to manufacturers’ protocols. Quantitative PCR reactions were performed 
with SybrGreen Master Mix (Agilent Technologies, Cheshire, UK) and run 
on an MX3000P Real-Time PCR System (Stratagene, Cheshire, UK). To 
detect the expression of transgenes, determine AAV6 titres and detect the 
expression of downstream genes, the following primers were used: forward 
NRF2 (150 nmol/l), 5′-TGGAGGCAGCCATGACTGA-3′; reverse NRF2 
(300 nmol/l), 5′-CTGCTTGTTTTCGGTATTAAGACACT-3′; forward 
PRDX3 (300 nmol/l), 5′-GCAGCTGCGGGAAGGTT-3′; reverse PRDX3 
(150 nmol/l), 5′- GGCAGAAATACTCCGGGAAAT-3′; forward HO1 
(900 nmol/l), 5′-CACTTCGTCAGAGGCCTGCTA-3′; reverse HO1 
(900 nmol/l), 5′-GCGGTGTCTGGGATGAGCTA-3′; forward NQO1 
(600 nmol/l), 5′-CGCCTGAGCCCAGATATTGT-3′; reverse NQO1 (300 
nmol/l), 5′-ACTGCAATGGGAACTGAAATATCA-3′. β-actin was used 
as the housekeeping gene with the following primers: forward actin (900 
nmol/l), 5′-ATGCTCCCCGGGCTGTAT-3′; reverse actin (300 nmol/l), 
5′-CATAGGAGTCCTTCTGACCCATTC-3′.
Western blotting. Proteins were extracted from cells or tissues, separated on 
8.5–15% SDS-polyacrylamide gels depending on the molecular weight of 
the protein of interest, and transferred to a polyvinylidenedifluoride mem-
brane (Merck Millipore, Billerica, MA). The following primary antibod-
ies were used: mouse antibody to PRDX3 (Ab16751, Abcam, Cambridge, 
UK), goat antibody to NRF2 (Ab31163, Abcam), rabbit antibody to NQO1 
(Ab80588, Abcam), rabbit antibody to HO1 (Ab13243, Abcam), and rabbit 
antibody to β-actin (Ab8227, Abcam). They were followed by horserad-
ish peroxidase-conjugated secondary antibodies chosen according to the 
protein(s) of interest: rabbit antibody to goat (P0449, Dako, Ely, UK), goat 
antibody to mouse (170–6516, Biorad, Hemel Hempstead, UK), goat anti-
body to rabbit (P0448, Dako), and swine antibody to rabbit (P0217, Dako).
Animals. All procedures were carried out according to the UK Home 
Office regulations. All mice used in this project were housed singly, were 
provided with standard chow and water ad libitum, and were exposed to 
an automated 12 hour light–dark cycle at 24 °C. The congenic C57BL/6J Tg 
(SOD1 G93A)1Gur (G93A-SOD1) mice (Jackson Laboratory, Bar Harbor, 
ME) were used,46 which were backcrossed onto the wild-type C57BL/6 
mice (Charles River Laboratories, Wilmington, MA) for >10 generations. 
A priori power analysis showed that 15 animals per group was a sufficient 
sample size to detect a medium effect with an 80% power. Transgenic 
mice (genotyped according to the Jackson Laboratory protocols) were 
recruited in subgroups of four (one mouse per group; (i) no treatment, 
(ii) AAV6-GFP, (iii) AAV6-PRDX3, and (iv) AAV6-NRF2), and they were 
age-matched and if possible, litter-matched. A total volume of 120 μl of 
viral vector solution was injected intramuscularly per mouse (30 days of 
age ± 1 day) in various muscle groups (facial muscles, 20 μl; tongue, 10 
μl; intercostal muscles, 15 μl; diaphragm, 15 μl; hind limbs, 60 μl) using 
isoflurane anesthesia. Multiple injection sites were used per muscle group 
with a maximum of 5 μl solution per site administered slowly using a 10 
μl 33-Gauge Hamilton syringe (ESS Laboratory, Cranston, RI). Behavioral 
assessment and all in vivo tests were carried out blinded to treatment. All 
mice were weighed and scored twice per week until they reached 140 days 
of age, and from that point onwards they were weighed and scored daily. 
Rotarod tests were performed twice per week (2 trials per test, only best 
score was recorded). The rotarod was set to accelerate from 4 to 40 rpm 
(rotations per minute) in 300 seconds, and the latency to fall was recorded 
in seconds. The maximum time showing no motor impairment was 
defined as 300 seconds. In addition, gait analysis was performed using the 
automated footprint recording Catwalk system 7.1 (Noldus Information 
Technology, Wageningen, The Netherlands) every 10 days. Briefly, each 
mouse was allowed to run from one side to the other of a glass plate and a 
video camera underneath the glass plate recorded the video image of the 
run.
Histological analysis. When transgenic mice reached the endpoint (i.e., 
loss of righting reflex for >10 seconds or 30% weight loss from peak weight 
for 3 days), they were terminally anesthetized with pentobarbital and then 
transcardially perfused with phosphate-buffered saline supplemented with 
5 units/ml heparin (Sigma) followed by 4% paraformaldehyde inphos-
phate-buffered saline. After overnight incubation in 4% paraformalde-
hyde, all tissues were cryoprotected in 30% sucrose in phosphate-buffered 
saline for 1 day and subsequently cryoembedded in optimum cutting tem-
perature medium (Dako). Lumbar spinal cords were serially sectioned at 
10 µm thickness, and five sections were mounted per slide. Every other 
slide was used to determine motor neuron counts under a light microscope 
using the Nissl stain (0.1% Cresyl Fast Violet; BDH, Lutterworth, UK) for 
a total of 20 mice (five per group). Immunohistochemistry was performed 
to detect transduced motor neurons using the lumbar spinal cords of three 
mice treated were AAV6-GFP, and incubating them concomitantly with 
1:500 dilution of a rabbit antibody to GFP (AB290, Abcam) and 1:100 
dilution of a goat antibody to choline acetyltransferase (AB144P; Merck 
Millipore). The secondary antibodies incubations were performed sequen-
tially firstly with a donkey Alexa Fluor 568 antigoat antibody (A-11057, 
Invitrogen), and then with a goat FITC antirabbit antibody (111-095-003, 
Jackson ImmunoResearch, Suffolk, UK). The percentage of transduced 
neurons was determined by counting the cells exhibiting double staining. 
For western blot analysis, tissues were collected fresh after intracardiac per-
fusion with phosphate-buffered saline and snap frozen in liquid nitrogen.
Statistical analysis. Power analysis was conducted using GPower 3.0 soft-
ware (Dusseldorf University, Dusseldorf, Germany) and statistical analy-
sis was performed using GraphPad Prism v5 (GraphPad, San Diego, CA). 
Statistical significance was determined by one- or two-way analysis of vari-
ance depending on the number of variables under investigation and on 
individual experiment, as stated in figure legends. In figures, the asterisk 
is used to denote the statistical significance (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001), whereas its absence shows no statistical significance. In general, in 
cell survival assays the effect of the viral construct and the oxidative stress 
conditions were investigated concurrently to ensure that the number of 
untreated cells in the increased stress conditions is within the therapeu-
tic window and the compensatory ability of each therapeutic intervention 
in question for subsequent comparisons. In DCF assays, the experimental 
design of the procedure allowed the monitoring of the toxicity, and thus 
only the effect of the viral construct per stress condition was analyzed.
SUPPLEMENTARY MATERIAL
Figure S1. Gene transfer detection after viral delivery in post-mor-
tem SOD1G93A mouse tissues.
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